Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Arterial Vascular Engineering AVEI -- Ignore unavailable to you. Want to Upgrade?

To: igor who wrote (45)	2/14/1998 11:30:00 AM
From: AARON DIDICH	Respond to of 410

Igor: Not sure if they have a website that allows it and I am not going to type the whole thing out, quite long for a slooooow typer. If someone else can great, if not I will try and review and paraphrase the high points; have not read it myself and know that that section does not bash a stock so it will be a positive spin. Aaron

To: igor who wrote (45)	2/16/1998 3:00:00 PM
From: AARON DIDICH	Read Replies (1) \| Respond to of 410

Igor, Just getting around to your request and since no one else posted anything let me just hit the highlights: Article was written by Loren Fleckenstein, the original one I saw in 5/25/96 was written by Laura Benko. 1. The company reported $2.9M in US stent sales for the last three days of the 1997 cycle. NB: I reported on the Guidant thread of SI a source that revealed GDT was booking $4M/ day of new sales once they received approval. This was also after at least a month or more after approval so AVE may yet build up to that level...currently just slightly less than $1M/day. GDT also blew analyst's estimates out of the water due to those phenom sales. 2. AVE and two rivals, BSX and GDT will be the winners in this growing market 3. AVE is the only company to sell renal artery stents and will be launching a stent for degenerated vein grafts. NB: these are probably the so called saphenous vein grafts used to jump coronary artery blockages 4. timelines: May, 4th generation stent in Europe Summer: file clinical trials of above in US 5th generation stent on the drawing board 5. company has spent 20% of revenues for R&D and getting ready for the US launch, that should drop to a steady 14-6% but will be based on a larger revenue base. 6. Medicare increased reimbursement rates for stents this past Oct. 7. Nice bar graph showing sales: '97= $79 '98= $203.5E '99= $456E '00= $510E Hope this helps and hope that we get a nice buyout offer before yearend. Aaron